Volume | 1,514,117 |
|
|||||
News | - |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Grifols SA | GRFS | NASDAQ | Depository Receipt |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.59 | 6.54 | 6.67 | 6.57 | 6.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume |
---|---|---|---|---|
10,562 | 1,514,117 | 6.59 | 9,977,098 | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:42:07 | 1 | 6.6276 | USD |
Grifols SA Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.9B | 426.13M | - | 6.59B | 59.32M | 0.14 | 65.73 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News Grifols
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
GRFS Historical
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine we develop produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic rare and prevalent diseases sometimes life-threatening drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology hepatology and intensive care pulmonology hematology neurology and infectious diseases. With a workforce of over 27000 employees in more than 30 countries and regions we are committed to a sustainable business model that sets the standard for continuous innovation quality safety and ethical leadership in the industry. |